Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Profit After Tax (2018 - 2025)

10x Genomics (TXG) has disclosed Profit After Tax for 8 consecutive years, with -$16.3 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 66.85% to -$16.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$43.5 million through Dec 2025, up 76.16% year-over-year, with the annual reading at -$43.5 million for FY2025, 76.16% up from the prior year.
  • Profit After Tax hit -$16.3 million in Q4 2025 for 10x Genomics, up from -$27.5 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $34.5 million in Q2 2025 to a low of -$93.0 million in Q3 2023.
  • Historically, Profit After Tax has averaged -$35.3 million across 5 years, with a median of -$36.8 million in 2024.
  • Biggest five-year swings in Profit After Tax: plummeted 483.22% in 2022 and later skyrocketed 191.14% in 2025.
  • Year by year, Profit After Tax stood at -$18.4 million in 2021, then rose by 6.69% to -$17.2 million in 2022, then tumbled by 184.36% to -$49.0 million in 2023, then fell by 0.16% to -$49.0 million in 2024, then skyrocketed by 66.85% to -$16.3 million in 2025.
  • Business Quant data shows Profit After Tax for TXG at -$16.3 million in Q4 2025, -$27.5 million in Q3 2025, and $34.5 million in Q2 2025.